Imatinib as tyrosine kinase inhibitor inhibiting KIT/PDGFRA (platelet-derived growth factor receptor alpha) and their downstream signaling cascade in GIST cells is currently standard of care in the first-line therapy of inoperable and/or metastatic tumors [3], and became the model of targeted therapy of solid tumors. This evidence concerns the gene PDGFRA and metastatic neoplasm.